Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads

Michael A Kolber, Abdel H. Gabr, Abel De la Rosa, Jonathan A. Glock, Dushyantha T Jayaweera, Nancimae Miller, Gordon Dickinson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: In this study we evaluated the possibility that plasma viral load elevations secondary to influenza vaccination in HIV-1-seropositive individuals with previously undetectable viral loads (< 200 copies/ml) could develop resistance-bearing mutations in the viral reverse transcriptase (RT) and protease regions. Methods: Thirty-four patients with undetectable viral burdens on highly active antiretroviral therapy (HAART) were evaluated for elevations in plasma viral load 2 and 4 weeks post-influenza vaccination. Plasma from patients whose viral load increased after vaccination was subject to genotypic resistance analysis by the line probe assay (LiPA) to determine whether primary resistance-bearing mutations developed during this period and at follow-up. Stored plasma was used to evaluate whether RT or protease mutations existed pre-vaccination. Results: Seven out of 34 patients were found to experience elevations in their viral load after influenza vaccination. Two of the patients revealed evidence of primary RT or protease mutations not demonstrated in earlier pre-vaccination samples. One patient failed therapy after vaccination, and one patient revealed post-vaccination viral load elevations that eventually led to the progressive development of primary zidovudine mutations. Conclusion: Evidence is presented that supports the contention that a small subset of patients who experience viral load elevations after influenza vaccination can develop mutational changes in the RT region of the viral genome either acutely or after a failure of the viral load to return to undetectable levels.

Original languageEnglish
Pages (from-to)537-542
Number of pages6
JournalAIDS
Volume16
Issue number4
DOIs
StatePublished - Mar 8 2002

Fingerprint

Viral Load
Human Influenza
HIV-1
Vaccination
RNA
RNA-Directed DNA Polymerase
Mutation
Peptide Hydrolases
Zidovudine
Viral Genome
Highly Active Antiretroviral Therapy

Keywords

  • Antiretroviral therapy
  • Healthcare
  • HIV resistance mutations
  • Influenza
  • LiPA
  • Viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. / Kolber, Michael A; Gabr, Abdel H.; De la Rosa, Abel; Glock, Jonathan A.; Jayaweera, Dushyantha T; Miller, Nancimae; Dickinson, Gordon.

In: AIDS, Vol. 16, No. 4, 08.03.2002, p. 537-542.

Research output: Contribution to journalArticle

@article{879f5bd9234f4610832af4693152e6f3,
title = "Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads",
abstract = "Objective: In this study we evaluated the possibility that plasma viral load elevations secondary to influenza vaccination in HIV-1-seropositive individuals with previously undetectable viral loads (< 200 copies/ml) could develop resistance-bearing mutations in the viral reverse transcriptase (RT) and protease regions. Methods: Thirty-four patients with undetectable viral burdens on highly active antiretroviral therapy (HAART) were evaluated for elevations in plasma viral load 2 and 4 weeks post-influenza vaccination. Plasma from patients whose viral load increased after vaccination was subject to genotypic resistance analysis by the line probe assay (LiPA) to determine whether primary resistance-bearing mutations developed during this period and at follow-up. Stored plasma was used to evaluate whether RT or protease mutations existed pre-vaccination. Results: Seven out of 34 patients were found to experience elevations in their viral load after influenza vaccination. Two of the patients revealed evidence of primary RT or protease mutations not demonstrated in earlier pre-vaccination samples. One patient failed therapy after vaccination, and one patient revealed post-vaccination viral load elevations that eventually led to the progressive development of primary zidovudine mutations. Conclusion: Evidence is presented that supports the contention that a small subset of patients who experience viral load elevations after influenza vaccination can develop mutational changes in the RT region of the viral genome either acutely or after a failure of the viral load to return to undetectable levels.",
keywords = "Antiretroviral therapy, Healthcare, HIV resistance mutations, Influenza, LiPA, Viral load",
author = "Kolber, {Michael A} and Gabr, {Abdel H.} and {De la Rosa}, Abel and Glock, {Jonathan A.} and Jayaweera, {Dushyantha T} and Nancimae Miller and Gordon Dickinson",
year = "2002",
month = "3",
day = "8",
doi = "10.1097/00002030-200203080-00004",
language = "English",
volume = "16",
pages = "537--542",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads

AU - Kolber, Michael A

AU - Gabr, Abdel H.

AU - De la Rosa, Abel

AU - Glock, Jonathan A.

AU - Jayaweera, Dushyantha T

AU - Miller, Nancimae

AU - Dickinson, Gordon

PY - 2002/3/8

Y1 - 2002/3/8

N2 - Objective: In this study we evaluated the possibility that plasma viral load elevations secondary to influenza vaccination in HIV-1-seropositive individuals with previously undetectable viral loads (< 200 copies/ml) could develop resistance-bearing mutations in the viral reverse transcriptase (RT) and protease regions. Methods: Thirty-four patients with undetectable viral burdens on highly active antiretroviral therapy (HAART) were evaluated for elevations in plasma viral load 2 and 4 weeks post-influenza vaccination. Plasma from patients whose viral load increased after vaccination was subject to genotypic resistance analysis by the line probe assay (LiPA) to determine whether primary resistance-bearing mutations developed during this period and at follow-up. Stored plasma was used to evaluate whether RT or protease mutations existed pre-vaccination. Results: Seven out of 34 patients were found to experience elevations in their viral load after influenza vaccination. Two of the patients revealed evidence of primary RT or protease mutations not demonstrated in earlier pre-vaccination samples. One patient failed therapy after vaccination, and one patient revealed post-vaccination viral load elevations that eventually led to the progressive development of primary zidovudine mutations. Conclusion: Evidence is presented that supports the contention that a small subset of patients who experience viral load elevations after influenza vaccination can develop mutational changes in the RT region of the viral genome either acutely or after a failure of the viral load to return to undetectable levels.

AB - Objective: In this study we evaluated the possibility that plasma viral load elevations secondary to influenza vaccination in HIV-1-seropositive individuals with previously undetectable viral loads (< 200 copies/ml) could develop resistance-bearing mutations in the viral reverse transcriptase (RT) and protease regions. Methods: Thirty-four patients with undetectable viral burdens on highly active antiretroviral therapy (HAART) were evaluated for elevations in plasma viral load 2 and 4 weeks post-influenza vaccination. Plasma from patients whose viral load increased after vaccination was subject to genotypic resistance analysis by the line probe assay (LiPA) to determine whether primary resistance-bearing mutations developed during this period and at follow-up. Stored plasma was used to evaluate whether RT or protease mutations existed pre-vaccination. Results: Seven out of 34 patients were found to experience elevations in their viral load after influenza vaccination. Two of the patients revealed evidence of primary RT or protease mutations not demonstrated in earlier pre-vaccination samples. One patient failed therapy after vaccination, and one patient revealed post-vaccination viral load elevations that eventually led to the progressive development of primary zidovudine mutations. Conclusion: Evidence is presented that supports the contention that a small subset of patients who experience viral load elevations after influenza vaccination can develop mutational changes in the RT region of the viral genome either acutely or after a failure of the viral load to return to undetectable levels.

KW - Antiretroviral therapy

KW - Healthcare

KW - HIV resistance mutations

KW - Influenza

KW - LiPA

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0037040359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037040359&partnerID=8YFLogxK

U2 - 10.1097/00002030-200203080-00004

DO - 10.1097/00002030-200203080-00004

M3 - Article

C2 - 11872996

AN - SCOPUS:0037040359

VL - 16

SP - 537

EP - 542

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -